IN2014CN03580A - - Google Patents

Info

Publication number
IN2014CN03580A
IN2014CN03580A IN3580CHN2014A IN2014CN03580A IN 2014CN03580 A IN2014CN03580 A IN 2014CN03580A IN 3580CHN2014 A IN3580CHN2014 A IN 3580CHN2014A IN 2014CN03580 A IN2014CN03580 A IN 2014CN03580A
Authority
IN
India
Prior art keywords
block copolymer
chain segment
based drug
amino acid
present
Prior art date
Application number
Other languages
English (en)
Inventor
Kazunori Kataoka
Takehiko Ishii
Mitsuru Naito
Akira Matsumoto
Yasuki Kato
Original Assignee
Univ Tokyo
Nat Univ Corp Tokyo Med & Dent
Nanocarrier Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo, Nat Univ Corp Tokyo Med & Dent, Nanocarrier Co Ltd filed Critical Univ Tokyo
Publication of IN2014CN03580A publication Critical patent/IN2014CN03580A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40Polyamides containing oxygen in the form of ether groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/42Polyamides containing atoms other than carbon, hydrogen, oxygen, and nitrogen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
IN3580CHN2014 2011-11-17 2012-11-19 IN2014CN03580A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161561022P 2011-11-17 2011-11-17
PCT/JP2012/079897 WO2013073697A1 (ja) 2011-11-17 2012-11-19 フェニルボロン酸基が導入されたブロックコポリマーおよびその使用

Publications (1)

Publication Number Publication Date
IN2014CN03580A true IN2014CN03580A (enExample) 2015-10-09

Family

ID=48429749

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3580CHN2014 IN2014CN03580A (enExample) 2011-11-17 2012-11-19

Country Status (13)

Country Link
US (1) US9114177B2 (enExample)
EP (1) EP2781536B1 (enExample)
JP (1) JP5481614B2 (enExample)
KR (1) KR101912978B1 (enExample)
CN (1) CN104093768B (enExample)
AU (1) AU2012337721B2 (enExample)
BR (1) BR112014011831A2 (enExample)
CA (1) CA2853902A1 (enExample)
ES (1) ES2603632T3 (enExample)
IN (1) IN2014CN03580A (enExample)
MX (1) MX2014005540A (enExample)
RU (1) RU2014124333A (enExample)
WO (1) WO2013073697A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828700A1 (en) 2011-03-31 2012-10-04 Nanocarrier Co., Ltd. Pharmaceutical composition containing block copolymer comprising boronic acid compound
EP2842546A4 (en) 2012-04-27 2015-12-30 Univ Tokyo PHARMACEUTICAL COMPOSITION WITH UNIT STRUCTURE FOR NUCLEIC ACID RELIEF
WO2015121924A1 (ja) 2014-02-12 2015-08-20 一般社団法人医療産業イノベーション機構 mRNA送達用組成物
WO2015170757A1 (ja) * 2014-05-08 2015-11-12 国立大学法人 東京大学 医薬組成物
KR101891655B1 (ko) * 2016-05-17 2018-08-24 기초과학연구원 페닐보론산이 결합된 고분자를 포함하는 약물 전달체
US10973762B2 (en) 2016-08-02 2021-04-13 Nippon Kayaku Kabushiki Kaisha Active-targeting-type polymer derivative, composition containing said polymer derivative, and uses of said polymer derivative and said composition
EP3501544B1 (en) * 2016-08-22 2021-07-28 Tokyo Institute of Technology Ligand capable of multivalently binding to glutamine transporter, and composition comprising same
CN111050752B (zh) * 2017-08-31 2022-08-16 国立大学法人东京大学 搭载核酸的单元型聚离子复合物
KR102075476B1 (ko) * 2017-12-29 2020-02-10 포항공과대학교 산학협력단 페닐보론산이 결합된 고분자를 포함하는 하이드로겔
JP7568511B2 (ja) 2018-04-27 2024-10-16 ジーンエディット インコーポレイテッド カチオン性ポリマーおよびその生体分子送達のための使用
WO2020067142A1 (en) 2018-09-25 2020-04-02 The University Of Tokyo Amphiphilic poly(amino acid), block copolymer using the amphiphilic poly(amino acid), and complex including the amphiphilic poly(amino acid) or the block copolymer and nucleic acid
JP7536258B2 (ja) * 2019-05-29 2024-08-20 国立大学法人東京工業大学 複合体、医薬、癌治療剤、キット及び結合体
WO2021055759A1 (en) 2019-09-20 2021-03-25 Glyscend, Inc. Substituted phenyl boronic acid containing polymers and methods of use
KR102510170B1 (ko) * 2020-10-07 2023-03-14 포항공과대학교 산학협력단 활성산소종 감응성을 가지는, 고분자가 코팅된 금 나노입자-압타머 나노구조체의 개발 및 응용
WO2022191107A1 (ja) * 2021-03-10 2022-09-15 Agc株式会社 含ハロゲン部位を有するポリマーおよび該ポリマーを用いた医薬組成物
CN114163591B (zh) * 2021-11-29 2023-08-01 南方医科大学 一种嵌段共聚物、嵌段共聚物载药胶束及其制备方法和应用
CN114533669B (zh) 2022-01-18 2022-11-04 武汉大学 一种口腔护理组合物及其制备方法和应用
CN114632145B (zh) * 2022-03-07 2024-02-27 浙江大学 一种负载胰岛素的苯硼酸/脂肪酸双改性ε-聚赖氨酸颗粒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3257029B2 (ja) * 1992-04-22 2002-02-18 日本油脂株式会社 フェニルボロン酸誘導体及び製造方法
JPH083172A (ja) * 1994-06-15 1996-01-09 Nippon Oil & Fats Co Ltd フェニルボロン酸誘導体および製造方法
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JP2002179683A (ja) * 2000-12-13 2002-06-26 Japan Science & Technology Corp ポリアミノ酸誘導体から成る核酸関連物質反応試薬
DK2077293T3 (da) 2006-10-19 2011-08-15 Nanocarrier Co Ltd Blokcopolymer til lægemiddelkonjugater samt disses farmaceutiske sammensætninger
WO2008106129A2 (en) 2007-02-26 2008-09-04 Wisconsin Alumni Research Foundation Polymeric micelles for combination drug delivery
US8980241B2 (en) 2008-05-02 2015-03-17 University Of Tsukuba Polymerized cyclic nitroxide radical compound and use thereof
CA2724455A1 (en) 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
DK2281576T3 (da) 2008-07-29 2013-10-28 Nanocarrier Co Ltd Aktiv målsøgende polymermicelle med deri indkapslet medikament samt medicinsk sammensætning
KR101661746B1 (ko) 2008-08-13 2016-09-30 캘리포니아 인스티튜트 오브 테크놀로지 캐리어 나노입자, 그리고 관련된 조성물, 방법 및 시스템
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
JP5622188B2 (ja) * 2010-01-05 2014-11-12 独立行政法人物質・材料研究機構 フェニルボロン酸系単量体及びフェニルボロン酸系重合体
JP2011173960A (ja) 2010-02-23 2011-09-08 Univ Of Tsukuba 高分子ミセル型光刺激応答性一酸化窒素供与体
CA2828700A1 (en) 2011-03-31 2012-10-04 Nanocarrier Co., Ltd. Pharmaceutical composition containing block copolymer comprising boronic acid compound

Also Published As

Publication number Publication date
AU2012337721B2 (en) 2015-12-10
US20150051347A1 (en) 2015-02-19
RU2014124333A (ru) 2015-12-27
US9114177B2 (en) 2015-08-25
CN104093768B (zh) 2016-09-21
AU2012337721A1 (en) 2014-05-22
ES2603632T3 (es) 2017-02-28
CA2853902A1 (en) 2013-05-23
EP2781536B1 (en) 2016-08-17
EP2781536A1 (en) 2014-09-24
CN104093768A (zh) 2014-10-08
JP5481614B2 (ja) 2014-04-23
EP2781536A4 (en) 2015-06-10
KR101912978B1 (ko) 2018-10-29
BR112014011831A2 (pt) 2017-05-09
WO2013073697A1 (ja) 2013-05-23
MX2014005540A (es) 2014-09-22
JPWO2013073697A1 (ja) 2015-04-02
KR20140106511A (ko) 2014-09-03

Similar Documents

Publication Publication Date Title
IN2014CN03580A (enExample)
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MY165908A (en) Heterocyclic compound and use thereof
UA107112C2 (uk) Активатори розчинної гуанілатциклази
MX341732B (es) Inhibidores de la demetilasa lsd1 basados en arilciclopropilamina y sus usos médicos.
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
PH12013500872A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
MY166789A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX352245B (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
TW201129554A (en) 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
GEP20166448B (en) Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201001749A1 (ru) Способ лечения недифференцированного артрита
MX2010009837A (es) Tiazolil-dihidro-indazoles.
TN2011000531A1 (en) 5- alkynyl - pyridines
MX2013013403A (es) Modificaciones cristalinas estables de cloruro de dotap.
MX2013011096A (es) Metodos de tratamiento dirigido a degeneracion lobular frontotemporal.
IN2012DN06600A (enExample)
TN2011000530A1 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
UA33198U (ru) Способ коррекции иммунокомплексного спектра крови у больных соматоформными депрессивными расстройствами
TN2011000049A1 (en) 5-alkynyl-pyrimidines